nifedipine has been researched along with tamoxifen in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 3 (10.71) | 18.2507 |
| 2000's | 9 (32.14) | 29.6817 |
| 2010's | 15 (53.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belas, F; Chaudhary, AK; Cvetkovic, M; Dempsey, PJ; Fromm, MF; Kim, RB; Leake, B; Roden, DM; Roden, MM; Wandel, C; Wilkinson, GR; Wood, AJ | 1 |
| Bacsó, Z; Cianfriglia, M; Fenyvesi, F; Goda, K; Kappelmayer, J; Lustyik, G; Nagy, H; Szabó, G; Szilasi, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Sen, S; Sinha, N | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bharate, SS; Vishwakarma, RA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kessel, D | 1 |
| Bracke, M; Bruyneel, E; Castronovo, V; Charlier, C; Lechanteur, C; Mareel, M | 1 |
| Marzo, A; Monti, NC; Vuksic, D | 1 |
| Kagaya, A; Kurata, K; Morinobu, S; Takebayashi, M; Yamawaki, S | 1 |
| Cantrell, VE; Eckstein, J; Hall, SD; Hamman, MA; Jones, DR; Ring, BJ; Ruterbories, K; Williams, JA; Wrighton, SA | 1 |
| Barry, WH; Li, F; Su, Z; Sugishita, K | 1 |
| Assreuy, AM; Coelho, RR; Criddle, DN; Meireles, AV; Santos, GC; Scarparo, HC; Soares, PM; Souza, EP | 1 |
| Ali, RY; Matheny, CJ; Pollack, GM; Yang, X | 1 |
| Becklund, BR; Boulware, MI; Groth, RD; Kuo, SP; Mermelstein, PG; Weick, JP | 1 |
| Dharmala, K; Lee, CH; Yoo, JW | 1 |
| Cedillo, FD; Cervera, EG; Cordoba, J; Quijano, K; Ramos, ML; Valverde, LF | 1 |
| Deshpande, SB; Pandey, AK | 1 |
1 review(s) available for nifedipine and tamoxifen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
27 other study(ies) available for nifedipine and tamoxifen
| Article | Year |
|---|---|
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Resistance, Multiple; Enzyme Inhibitors; Humans; Male; Mice; Oxidoreductases, N-Demethylating; Pharmacokinetics; Substrate Specificity | 1999 |
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
Topics: Drug Discovery; Pharmaceutical Preparations; Solubility; Thermodynamics | 2015 |
Interactions among membrane transport systems: anthracyclines, calcium antagonists and anti-estrogens.
Topics: Animals; Antibiotics, Antineoplastic; Biological Transport; Calcium Channel Blockers; Daunorubicin; Doxorubicin; Drug Resistance; Estrogen Antagonists; Kinetics; Leukemia P388; Mice; Naphthacenes; Nifedipine; Nitrendipine; Tamoxifen; Verapamil | 1986 |
Enhancement of tamoxifen-induced E-cadherin function by Ca2+ channel antagonists in human breast cancer MCF7/6 cells.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cadherins; Calcium Channel Agonists; Calcium Channel Blockers; Cell Aggregation; Humans; Nifedipine; Tamoxifen; Tumor Cells, Cultured; Verapamil | 1996 |
Experimental, extrapolated and truncated areas under the concentration-time curve in bioequivalence trials.
Topics: Anticarcinogenic Agents; Area Under Curve; Biological Availability; Clinical Trials as Topic; Humans; Nifedipine; Reference Values; Tamoxifen; Therapeutic Equivalency; Vasodilator Agents | 1999 |
Effect of beta-estradiol on voltage-gated Ca(2+) channels in rat hippocampal neurons: a comparison with dehydroepiandrosterone.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Androstenedione; Animals; Azlocillin; Calcium; Calcium Channel Blockers; Calcium Channels; Cells, Cultured; Corticosterone; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dizocilpine Maleate; Estradiol; Estrogen Antagonists; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Hippocampus; Imidazolidines; N-Methylaspartate; Neurons; Nifedipine; Rats; Rats, Wistar; Tamoxifen | 2001 |
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Topics: Alprazolam; Aryl Hydrocarbon Hydroxylases; Biotransformation; Clarithromycin; Coumarins; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Cytochromes b5; Diltiazem; Estradiol; Humans; In Vitro Techniques; Kinetics; Microsomes, Liver; Midazolam; Nifedipine; Tamoxifen; Testosterone; Triazolam | 2002 |
Anti-oxidant effects of estrogen reduce [Ca2+]i during metabolic inhibition.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Animals; Antioxidants; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium-Transporting ATPases; Estriol; Estrogen Antagonists; Estrogens; Estrone; Male; Mice; Myocytes, Cardiac; Nifedipine; Sodium-Potassium-Exchanging ATPase; Tamoxifen; Testosterone | 2003 |
Effects of chloride channel blockers on hypotonicity-induced contractions of the rat trachea.
Topics: Animals; Chloride Channels; Hypotonic Solutions; Male; Muscle Contraction; Nifedipine; Niflumic Acid; Rats; Rats, Wistar; Tamoxifen; Trachea | 2004 |
Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues.
Topics: Actins; Administration, Oral; Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Brain; Cytochrome P-450 CYP3A; Dexamethasone; Drug Administration Schedule; Enzyme Induction; Gene Expression Regulation; Hypericum; Intestine, Small; Intubation; Liver; Male; Mice; Mice, Inbred Strains; Nifedipine; Oxidoreductases, N-Demethylating; Plant Extracts; Pregnane X Receptor; Pregnenolone Carbonitrile; Protein Isoforms; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rifampin; Tamoxifen; Time Factors | 2004 |
Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein.
Topics: Animals; Animals, Newborn; Blotting, Western; Calcium Channel Blockers; Calcium Channels; Cell Membrane; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Activation; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Fluorescent Antibody Technique; Gene Expression Regulation; Hippocampus; Humans; Inositol 1,4,5-Trisphosphate Receptors; Male; Microtubule-Associated Proteins; Nifedipine; Phosphorylation; Potassium; Protein Kinase C; Pyramidal Cells; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Metabotropic Glutamate; Sex Factors; Signal Transduction; Tamoxifen; Time Factors; Type C Phospholipases | 2005 |
Development of chitosan-SLN microparticles for chemotherapy: in vitro approach through efflux-transporter modulation.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Biological Transport; Chitosan; Drug Carriers; Drug Delivery Systems; Drug Therapy; Isothiocyanates; Lipids; Nanoparticles; Nifedipine; Particle Size; Tamoxifen; Verapamil | 2008 |
Changes induced by estradiol-ethylenediamine derivative on perfusion pressure and coronary resistance in isolated rat heart: L-type calcium channel.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Animals; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Coronary Circulation; Cyclooxygenase Inhibitors; Estradiol; Estrogen Antagonists; Ethylenediamines; Female; In Vitro Techniques; Indomethacin; Metoprolol; Myocardium; Nifedipine; Prazosin; Rats; Rats, Wistar; Tamoxifen; Vascular Resistance | 2011 |
Bisphenol A depresses compound action potential of frog sciatic nerve in vitro involving Ca(2+)-dependent mechanisms.
Topics: Action Potentials; Animals; Benzhydryl Compounds; Calcium; Calcium Channel Blockers; Diltiazem; Electric Stimulation; Electrodes; Electrophysiological Phenomena; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens, Non-Steroidal; In Vitro Techniques; Nickel; Nifedipine; Phenols; Ranidae; Sciatic Nerve; Tamoxifen | 2012 |